Intervention, treatment and management of ADHD

The International Handbook on Psychopathic Disorders and the Law: Diagnosis and Treatment

Volumn , Issue , 2010, Pages 381-395

  Herpertz Dahlmann, Beate ^a   Konrad, Kerstin ^a   Herpertz, Sabine C ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Dialectical behavior treatment; Dopaminergic and noradrenergic neurotransmission; Hyperactivity impulsivity symptoms; Norepinephrine reuptake inhibitor; Of adult antisocial personality disorder

Indexed keywords

EID: 84889279556     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470516157.ch23     Document Type: Chapter

References (61)

1. Abikoff, H., Hechtman, L., Klein, R.G. et al. (2004a). Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 802-11.
2. Abikoff, H., Hechtman, L., Klein, R.G. et al. (2004b). Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 820-9.
3. Allen, A., Kurlan, R., Gilbert, D. et al. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941-9.
4. American Academy of Child and Adolescent Psychiatry (AACAP) (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 26S-49S.
5. Banaschewski, T., Coghill, D., Santosh, P. et al. (2006). Long-acting medications for the hyperkinetic disorders. European Child and Adolescent Psychiatry, published online.
6. Bangs, M., Emslie, G., Spencer, T. et al. (2005). A study of atomoxetine in adolescents with ADHD and comorbid depression. Paper presented at 45th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), June 6-9, Boca Raton, FL.
7. Barkley, R.A. (1990). Attention-deficit and hyperactivity disorder. A Handbook for Diagnosis and Treatment. New York: Guildford Press.
8. Barkley, R.A. (1998). Attention-deficit and hyperactivity disorder. A Handbook for Diagnosis and Treatment, second edition. New York: Guilford Press.
9. Barkley, R.A., Fischer, M., Smallish, L. & Fletcher, K. (2003). Does the treatment of attentiondeficit/ hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics, 3, 97-109.
10. Bedard, A.C., Ickowicz, A., Logan, G.D. et al. (2003). Selective inhibition in children with attentiondeficit hyperactivity disorder off and on stimulant medication. Journal of Abnormal Child Psychology, 31, 315-27.
11. Biederman, J. & Faraone, S.V. (2005). Attention-deficit hyperactivity disorder. Lancet, 366, 237-48.
12. Biederman, J., Thisted, R., Greenhill, L. & Ryan, N. (1995). Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year old children. Journal of Clinical Psychiatry, 56, 87-93.
13. Charach, A., Figueroa, M., Chen, S. et al. (2006). Stimulant treatment over 5 years: effects on growth. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 415-21.
14. Connor, D., Glatt, S., Lopez, I. et al. (2002). Psychopharmacology and aggression-related behaviors in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 253-61.
15. Denney, C. & Rapport, M. (2001). The cognitive pharmacology of stimulants in children with ADHD. In M.V. Solanto, A.F.T. Arnsten & F.X. Castellanos (eds.), Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (pp. 283-302). New York: Oxford University Press.
16. Dodson, W.W. (2005). Pharmacotherapy of adult ADHD. Journal of Clinical Psychology, 61, 589-606.
17. Epstein, J.N., Conners, C.K., Hervey, A.S. et al. (2006). Assessing medication effects in theMTAstudy using neuropsychological outcomes. Journal of Child Psychology and Psychiatry, 47, 446-56.
18. Faraone, S.V., Spencer, T., Aleardi, M. et al. (2004). Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology, 24, 24-9.
19. Faraone, S.V. &Wilens, T. (2003). Does stimulant treatment lead to substance use disorders? Journal of Clinical Psychiatry, 64, 9-13.
20. Greenhill, L., Pliszka, S., Dulcan, M.K. et al. (2001). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 26-49.
21. Hart, E.L., Lahey, B.B., Loeber, R. et al. (1995). Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. Journal of Abnormal Child Psychology, 23, 729-49.
22. Hechtman, L. (2006). Long-term treatment of children and adolescents with attentiondeficit/ hyperactivity disorder (ADHD). Current Psychiatry Reports, 8, 398-408.
23. Hechtman, L., Abikoff, H., Klein, R.G. et al. (2004). Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 812-19.
24. Hechtman, L., Weiss, G. & Perlman, T. (1984). Young adult outcome of hyperactive children who received long-term stimulant treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 23, 261-9.
25. Herpertz-Dahlmann, B. (2001). Conduct disorders, antisocial behaviour, delinquency. In H. Remschmidt (ed.), Psychotherapy with Children and Adolescents (pp. 498-511). Cambridge, UK:Cambridge University Press.
26. Hesslinger, B., Tebartz van Elsst, L., Nyberg, E. et al. (2002). Psychopathy of attention deficit hyperactivity disorder in adults - a pilot study using a structured skills training program. European Archives of Psychiatry and Clinical Neuroscience, 252, 177-84.
27. Hoare, P., Remschmidt, H., Medori, R. et al. (2005). 12-month efficacy and safety of OROS? MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry, 14, 305-9.
28. Jensen, P.S., Hinshaw, S.P., Kraemer, H.C. et al. (2001). ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 147-58.
29. Kempton, S., Vance, A., Maruff, P. et al. (1999). Executive function and attention-deficit/hyperactivity disorder: stimulant medication and better executive function performance in children. Psychological Medicine, 29, 527-38.
30. Konrad, K., Günther, T., Gutenbrunner, M. & Herpertz-Dahlmann, B. (2005). Clinical evaluation of subjective and objective changes in motor activity and attention in children with attentiondeficit/ hyperactivity disorder in a double-blind methylphenidate trial. Journal of Child and Adolescent Psychopharmacology, 15, 821-8.
31. Konrad, K., Günther, T., Hanisch, C. & Herpertz-Dahlmann, B. (2004). Differential effects of methlyphenidate on attentional functions in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 191-8.
32. Konrad, K., Neufang, S., Hanisch, C. et al. (2006). Dysfunctional attentional networks in children with attention deficit/hyperactivity disorder (ADHD) - evidence from an event-related fMRI study. Biological Psychiatry, 59, 643-51.
33. Kratochvil, C.J., Vaughan, B.S., Harrington, M.J. & Burke, W.J. (2003). Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Pharmacotherapy, 4, 1165-74.
34. Kutcher, S., Aman, M., Brooks, S. et al. (2004). International consensus statement on attentiondeficit/ hyperactivity disorder (ADHD) and disruptive disorders (DBDs): clinical implications and treatment practice suggestions. European Neuopsychopharmacology, 14, 11-28.
35. Lee, T.S., Lee, T.D., Lombroso, P.J. & King, R.A. (2004). Atomoxetine and tics in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 1068-9.
36. Markowitz, J.S., Straughn, A.B. & Patrick, K.S. (2003). Advances in the pharmacotherapy of attentiondeficit- hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy, 23, 1282-99.
37. McBurnett, K., Pfiffner, L.J., Willcutt, E. et al. (1999). Experimental cross-validation of DSM-IV types of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 17-24.
38. McCracken, J., Biederman, J., Greenhill, L. et al. (2003). Analog classroom assessment of a oncedaily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 673-83.
39. Michelson, D., Adler, L., Spencer, T. et al. (2003). Atomoxetine in adults withADHD:two randomized placebo-controlled studies. Biological Psychiatry, 53, 112-20.
40. Miller, A.R., Lalonde, C.E. & McGrail, K.M. (2004). Children’s persistence with methylphenidate therapy: a population-based study. Canadian Journal of Psychiatry, 49, 761-8.
41. MTA Cooperative Group (1999a). A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073-86.
42. MTA Cooperative Group (1999b). Moderators and mediators of treatment response for children with attention deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1088-96.
43. MTA Cooperative Group (2004a). National Institute of Mental Health multimodal treatment study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics, 113, 754-61.
44. MTA Cooperative Group (2004b). National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics, 113, 762-9.
45. Nissen, E. (2006). ADHD drugs and cardiovascular risk. New England Journal of Medicine, 354, 1445-8.
46. Patel, N., Crismon, L., Hoagwood, K. & Jensen, P. (2005). Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. Journal of Child and Adolescent Psychopharmacology, 15, 270-84.
47. Patrick, K.S., Gonzalez, M.A., Straughn, A.B. & Markowitz, J.S. (2005). New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Drug Delivery, 2, 121-43.
48. Pliszka, S.R., Crismon, L., Hughes, C. et al. (2006). The Texas children’s medication algorithm project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 642-57.
49. Pliszka, S.R., Browne, R.G., Olvera, R.L. &Wynne, S.K. (2000). A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 619-26.
50. Prince, J.B. (2006). Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents:update on new stimulant preparations, atomoxetine, and novel treatments. Child and Adolescent Psychiatric Clinics of North America, 15, 13-50.
51. Quaschner, K. (2001). Hyperkinetic disorders. In H. Remschmidt (ed.), Psychotherapy with Children and Adolescents (pp. 438-56). Cambridge, UK: Cambridge University Press.
52. Riccio, C.A., Reynolds, C.R., Lowe, P. & Moore, J.J. (2002). The continuous performance test: a window on the neural substrates for attention? Archives of Clinical Neuropsychology, 17, 235-72.
53. Safren, S.A., Otto, M.W., Sprich, S. et al. (2005). Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behaviour Research and Therapy, 43, 831-42.
54. Shatkin, J. (2004). Atomoxetine for the treatment of pediatric nocturnal enuresis. Journal of Child and Adolescent Psychpharmacology, 14, 443-7.
55. Spencer, T., Biederman, J., Coffey, B. et al. (1999). The 4-year course of tic disorders in boys with attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 842-7.
56. Spencer, T., Biederman, J. & Wilens, T. (2002). Attention-deficit/hyperactivity disorder. In S. Kutcher (ed.), Practical Child and Adolescent Psychopharmacology (pp. 230-64). Cambridge, UK: Cambridge University Press.
57. Stevenson, C.S., Whitmont, S., Bornholt, L. et al. (2002). A cognitive remediation programme for adults with attention deficit hyperactivity disorder. Australian and New Zealand Journal of Psychiatry, 36, 610-16.
58. Sumner, C.S., Donnelly, C., Lopez, F.A. et al. (2005). Atomoxetine treatment for pediatric patients with ADHS and comorbid anxiety. Presented at Annual Meeting of the American Psychiatric Association, May 21-6, Atlanta.
59. Tannock, R., Schachar, R. & Logan, G.D. (1995): Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. Journal of Abnormal Child Psychology, 23, 235-66.
60. Wernicke, J.F., Faries, D., Girod, D. et al. (2003). Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety, 26, 729-70.
61. Wilens, T., Faraone, S.V., Biederman, J. & Gunawardene, S. (2003). Does stimulant therapy of attention deficit hyperactivity disorder beget later substance abuse? Pediatrics, 111, 179-85.